Vico Therapeutics Advances VO659 with Twice-Annual Dosing in Phase 1/2 Trial for Huntington's Disease and Spinocerebellar Ataxias
核心洞察
Vico Therapeutics (搜索) has initiated patient dosing with a twice-annual regimen of VO659, an antisense oligonucleotide targeting CAG repeat (搜索) expansions in Huntington's disease (搜索) and spinocerebellar ataxias.
The company previously reported a 38% reduction in cerebrospinal fluid mutant HTT and 2.5% reduction in CSF Nf-L in HD patients at four months.
VO659 has received FDA IND clearance, with U.S.-based clinical trials planned for later this year to expand the global development program.
Vico Therapeutics (搜索) has commenced patient dosing in an expanded cohort using a twice-annual dosing regimen of VO659, marking a significant milestone in the development of this first-in-class antisense oligonucleotide (ASO) therapy for severe neurological diseases. The Phase 1/2a clinical study is evaluating VO659 across multiple European countries for the treatment of Huntington's disease (搜索) (HD), spinocerebellar ataxia type 3 (搜索) (SCA3), and spinocerebellar ataxia type 1 (搜索) (SCA1).
Targeting CAG Repeat Expansions
VO659 represents a novel therapeutic approach as the only clinical-stage treatment specifically designed to target the pathogenic CAG repeat (搜索) expansion that underlies all nine known polyglutamine diseases (搜索), including HD, SCA3, and SCA1. The therapy is engineered to preferentially reduce mutant huntingtin (搜索) (HTT) protein while preserving wild-type HTT expression, addressing a critical challenge in treating these genetic disorders.
The company previously reported encouraging preliminary results, demonstrating a 38% reduction of cerebrospinal fluid mutant HTT (mHTT) and a 2.5% reduction of CSF neurofilament light chain (Nf-L) in HD patients dosed with VO659 at four months. These biomarker changes suggest potential neuroprotective effects in the central nervous system.
Extended Dosing Regimen Shows Promise
The current Phase 1/2 study is assessing every six-month dosing regimens over 12 months to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamic effects of VO659 administered intrathecally. To date, several participants have been dosed, and VO659 has demonstrated a favorable safety profile with no serious adverse events reported.
"I am very encouraged by our earlier results showing significant reduction of mHTT directly in the central nervous system with a favorable CSF Nf-L profile early in the time course," said Micah Mackison, CEO of Vico Therapeutics (搜索). "The twice annual patient-friendly dosing regimens will enable us to assess longer-term safety and pharmacodynamic effects, taking advantage of VO659's long half-life."
Regulatory Progress and Global Expansion
Vico has achieved a significant regulatory milestone with the receipt of Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration. The company plans to initiate U.S.-based clinical trials for VO659 later this year, substantially expanding its global development program beyond the current European trials conducted under an approved Clinical Trial Application.
The European trial is registered on ClinicalTrials.gov under identifier NCT05822908, providing transparency and accessibility for the research community and patients.
Scientific Presentations and Mechanism Insights
At CHDI's 21st Annual HD Therapeutics Conference, Vico's scientific leadership will present new data highlighting VO659's distinctive mechanism of action. Chief Scientific Officer Nicole Datson, PhD, will present findings on the therapy's ability to inhibit multiple drivers of CAG repeat (搜索)-mediated toxicity, while Chief Medical Officer Scott Schobel, MD, will provide a clinical trial update.
The presentations will detail how VO659's exon 1-directed CAG repeat (搜索)-targeting approach represents a precision medicine strategy for addressing the underlying genetic cause of these devastating neurological disorders. This mechanism distinguishes VO659 from other therapeutic approaches that may target downstream effects rather than the root genetic cause.
Addressing Unmet Medical Need
Vico Therapeutics (搜索) is positioned as a clinical-stage genetic medicines company pioneering RNA-targeted therapies for severe neurological diseases caused by defined genetic mutations. The company's precision ASO platform is designed to selectively target disease-causing RNA while preserving normal gene function, addressing a critical need for patients with limited or no treatment options.
The advancement of VO659 represents a potentially transformative approach for patients with Huntington's disease (搜索) and spinocerebellar ataxias, conditions that currently lack disease-modifying treatments and carry significant morbidity and mortality burdens for affected individuals and their families.